Armpit Lump

Medically reviewed by Graham Rogers, MD on July 25, 2017 — Written by Kristeen Moore

What is an armpit
lump?

An armpit lump usually refers to the enlargement of at least one of the lymph nodes under your arm. Lymph nodes are small, oval-shaped glands that are located throughout the body. They play an important role in your body’s immune system.

The lump may feel small. In other cases, it may be extremely noticeable. Armpit lumps may be caused by cysts , infection, or irritation due to shaving or antiperspirant use. However, these lumps may also indicate a serious underlying health

condition.

Seek medical attention if you have an armpit lump that gradually becomes enlarged, isn’t painful, or doesn’t go away.

Causes
of armpit lumps

Most lumps are harmless and are usually the result of abnormal tissue growth. However, armpit lumps can be related to a more serious underlying health problem. You should have your doctor evaluate any unusual lumps you have.

The most common causes of armpit lumps are:

  • bacterial or viral infections
  • lipomas (harmless fat tissue growths)
  • a fibroadenoma (noncancerous fibrous tissue growth)
  • allergic reactions
  • adverse reactions to vaccinations
  • fungal infections
  • a breast cancer response
  • lymphoma (cancer of the lymphatic system)
  • leukemia (cancer of the blood cells)
  • lupus (an autoimmune disease that targets your joints and organs)

Armpit
lumps in women

Armpit lumps can occur in men and women of all ages. However, a lump under the arm could indicate breast cancer . Women should perform monthly breast self-exams and report any breast lumps to a doctor right away.

Note that breasts undergo hormonal changes during the menstrual cycle and may tend to feel more tender or lumpy during this time. This is completely normal. For the most accurate results, perform breast self-exams about one to three days after your period ends.

Diagnosing
armpit lumps

A thorough physical examination is the first step in diagnosing an armpit lump. Your doctor will ask you questions about any changes in the lump, as well any pain you have in the area. Palpation, or massage, is used to determine the consistency and texture of the lump. This method is done exclusively by hand as the doctor gently examines the lymph nodes.

In some cases, a physical exam may prove that the lump isn’t harmful. For example, benign lumps , such as lipomas, don’t require additional treatment. If a lump is bothersome, however, a doctor can recommend treatment options to remove it.

Based on the results of your physical examination, your doctor may order further testing to rule out infection, allergic reaction , or cancerous changes. Your doctor may order a combination of the following diagnostic tests:

  • complete blood count to measure the number of red and white blood cells in your system
  • chest or breast X-ray (mammogram), which is an imaging test that allows your doctor to see the lump better
  • biopsy , which involves removing a small piece of tissue from the lump for testing
  • allergy testing

Treating
armpit lumps

The course of treatment your doctor recommends depends on the underlying cause of the lump. Bacterial infections can be treated with oral antibiotics. After several days, the armpit lump should start to disappear as your body fights the infection. If the lump doesn’t respond to oral antibiotics, you may have to be hospitalized for intravenous (IV) antibiotics.

If your lump is associated with allergies, it should subside once you start medication and learn to avoid your allergy triggers.

In most cases, armpit lumps don’t require any treatment, just simple observation. If your doctor determines this is the case, you can use home remedies such as warm compresses and over-the-counter pain relievers to ease any discomfort. Lumps that don’t require treatment include those associated with:

  • lipomas
  • viral infections
  • fibroadenoma (noncancerous breast lumps)

If your armpit lumps are cancerous, your doctor may refer you to a specialist for further care. Treatment will depend on the type of cancer and what stage you’re in, and it may involve a combination of:

  • chemotherapy
  • radiation therapy
  • surgery

Outlook
for armpit lumps

The outlook for an armpit lump depends on its cause. For example, a lump that stems from a viral infection will eventually go away on its own. However, a lipoma, while harmless, does not go away on its own. A dermatologist can help you remove it.

The outlook for an armpit lump caused by cancer depends on a variety of factors, including the stage of cancer and whether the tumors have spread to other parts of the body. For the best chance of recovery, it’s important you go to a doctor early on for diagnosis and treatment.

Even if you don’t think the lump is harmful, it’s best to contact your doctor for an accurate diagnosis.

Medically reviewed by Graham Rogers, MD on July 25, 2017 — Written by Kristeen Moore

related stories

  • Lipoma (Skin Lumps)
  • Lymphoma Symptoms
  • What Are the Warning Signs of Breast Cancer?
  • Leukemia
  • Effects of Breast Cancer on the Body

READ THIS NEXT

  • Lipoma (Skin Lumps)

    A lipoma is a growth of fatty tissue that slowly develops under the skin. People of any age can develop it, but it's rare in children.

    READ MORE

  • Lymphoma Symptoms

    The early symptoms of lymphoma may be either nonexistent or mild and non-specific. Read on to learn more about them.

    READ MORE

  • What Are the Warning Signs of Breast Cancer?

    If you've noticed a sharp pain or lump in your breast, you may be wondering if it's breast cancer. Pain in the breast is rarely the first noticeable…

    READ MORE

  • Leukemia

    Leukemia is a cancer of the blood cells. Get the statistics on survival rates, find out the most common symptoms, diagnostic options, and treatments.

    READ MORE

  • Effects of Breast Cancer on the Body

    Breast cancer refers to cancer that begins in the cells within your breasts. It can spread from the breasts to other areas of the body, such as the…

    READ MORE

  • Biopsy

    Your doctor may find they need a sample of your cells to help diagnose an illness or identify a cancer. This removal of tissue or cells is called a…

    READ MORE

  • Leukemia vs. Lymphoma: What’s the Difference?

    Leukemia and lymphoma are blood cancers. Learn more about these conditions.

    READ MORE

  • Guide to Mammogram Images

    Mammograms can help your doctor identify breast cancer. Check out our image gallery and learn more about mammograms.

    READ MORE

  • Chemotherapy

    Radiation and chemotherapy are treatments for cancer. Side effects include easy bruising, mouth lesions, and infections.

    READ MORE

  • What Is an Allergic Reaction?

    An allergic reaction occurs when your body attacks a foreign substance, called an allergen. You can inhale, eat, and touch allergens that cause a…

    READ MORE

CMS Id: 22223
Client Version: 6e22c25f684ac604de9688b78fa6958f707d7b7d
Build Number: 20115

  • NCBINCBI Logo
  • Skip to main
    content
  • Skip to
    navigation
  • Resources
  • How To
  • About NCBI Accesskeys
My NCBI Sign in to NCBI Sign Out

PMC

US National Library of Medicine

National Institutes of Health
  • Advanced
  • Journal list
  • Help
  • Journal List
  • Medicine (Baltimore)
  • v.96(51); 2017 Dec
  • PMC5758204
Logo of medicine

Medicine (Baltimore). 2017 Dec; 96(51): e9312.
Published online 2017 Dec 22. doi:  [ 10.1097/MD.0000000000009312 ]
PMCID: PMC5758204
PMID: 29390502

Male occult breast cancer with axillary lymph node metastasis as the first manifestation

A case report and literature review
Ruixin Xu , MD,a,b Jianbin Li , MD, Yingjie Zhang , MD,b Hongbiao Jing , MD,c and Youzhe Zhu , MDa,b

Ruixin Xu

aMedicine and Life Sciences College of Shandong Academy of Medical Sciences, University of Jinan

bDepartment of Radiation Oncology

Find articles by Ruixin Xu

Yingjie Zhang

bDepartment of Radiation Oncology

Find articles by Yingjie Zhang

Hongbiao Jing

cDepartment of Pathology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.

Find articles by Hongbiao Jing

Youzhe Zhu

aMedicine and Life Sciences College of Shandong Academy of Medical Sciences, University of Jinan

bDepartment of Radiation Oncology

Find articles by Youzhe Zhu
Monitoring Editor: Prashant Thakkar.
Author information Article notes Copyright and License information Disclaimer
aMedicine and Life Sciences College of Shandong Academy of Medical Sciences, University of Jinan
bDepartment of Radiation Oncology
cDepartment of Pathology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.
Correspondence: Jianbin Li, Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China (e-mail: [email protected] ).
Received 2017 May 24; Revised 2017 Nov 24; Accepted 2017 Nov 27.
Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0

Abstract

Rationale:

Occult breast cancer (OBC) is extremely rare in males with neither symptoms in the breast nor abnormalities upon imaging examination.

Patient concerns:

This current case report presents a young male patient who was diagnosed with male OBC first manifesting as axillary lymph node metastasis. The physical and imaging examination showed no primary lesions in either breasts or in other organs.

Diagnoses:

The pathological results revealed infiltrating ductal carcinoma in the axillary lymph nodes. Immunohistochemical (IHC) staining was negative for estrogen receptor (ER), progesterone receptor (PR), cytokeratin (CK)20 and thyroid transcription factor-1 (TTF-1), positive for CK7, gross cystic disease fluid protein-15 (GCDFP-15), epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA), and suspicious positive for human epidermal receptor-2 (Her-2). On basis of IHC markers, particularly such as CK7, CK20 and GCDFP-15, and eliminating other malignancies, male OBC was identified in spite of negativity for hormone receptors.

Interventions:

The patient underwent left axillary lymph node dissection (ALND) but not mastectomy. After the surgery, the patient subsequently underwent chemotherapy and radiotherapy.

Outcomes:

The patient is currently being followed up without any signs of recurrence.

Lessons:

Carefully imaging examination and pathological analysis were particularly essential in the diagnosis of male OBC. The guidelines for managing male OBC default to those of female OBC and male breast cancer.

Keywords: axillary lymph node metastasis, immunohistochemical staining, male, occult breast cancer

1. Introduction

Male breast cancer (MBC) is a rare but important condition accounting for only 1% of all breast cancer worldwide and less than 1% of all male malignancies. Male OBC is an extremely rare type of MBC that is asymptomatic in the breast and is normally detected by palpable lumps in the axilla, similar to the OBC in females. The case we reported here is a young male patient diagnosed with occult breast cancer. He had no significant medical history, and the initial clinical symptom was axillary lymph node metastasis. He underwent left axillary lymph node dissection (ALND) twice but without mastectomy. Herein, by reviewing the relevant literatures, we introduce a case of the male OBC and explore its clinical, imageological, and pathological features and the management. This study was approved by the institutional research ethics board of Shandong Cancer Hospital. Written informed consent was obtained from the patient.

2. Case presentation

The patient, a 29-year-old male, discovered a painless half-peanut-size nodule in his left axilla in April 2014. The patient was not concerned because of his busy daily work schedule. The size of the nodule gradually increased in the following year. In March 2016, he went to a local hospital near his home for a medical checkup and exhibiting 2 walnut-sized palpable masses. Ultrasonographic (US) examination revealed 3 hypoechoic solid masses with clear boundaries in the left axillary cavity (Fig. (Fig.1);1 ); the largest mass was 4.3 cm × 2.3 cm in diameter, and the first-stage diagnosis was “The solid masses in the left axilla.” He then went to the surgical department for further examination and treatment. Physical examination in the left axilla showed 2 rigid, mobile, painless masses measuring approximately 5 cm in diameter, and the skin covering the masses was normal. After admission to the hospital, all tumor markers, such as serum carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), alpha fetoprotein (AFP), prostate specific antigen (PSA), cytokeratin 19 fragment (Cyfra21–1), carbohydrate antigen 19–9 (CA19–9), and carbohydrate antigen 72–4 (CA72–4), were within normal ranges. Both routine hematological and biochemical parameters were normal. On March 16, 2016, the patient underwent his first surgery for axillary neoplasm resection and left axillary lymph node dissection (ALND). The pathological report of the local hospital (with consultation from the superior hospital expert) stated that only metastatic lymph nodes were found in the left axilla with no suspicious lesions in the resected specimen. A poorly differentiated carcinoma was found in the lymph nodes (infiltrating ductal carcinoma, IDC; 14 out of 15 dissected axillary lymph nodes showed metastasis), and according to IHC staining, the probability that it metastasized from breast cancer could not be ruled out. The IHC results were positive for cytokeratin (CK), gross cystic disease fluid protein 15 (GCDFP-15) and human epidermal receptor 2 (Her-2) (++) and negative for estrogen receptor (ER), progesterone receptor (PR), CK5/6, CK20, caudal-related homeobox transcription factor 2 (CDX-2), P63, thyroid transcription factor 1 (TTF-1), synaptophysin (Syn), chromogranin A (CgA), and S100. A chest computed tomography (CT) scan was performed in the local hospital 8 days after the operation, and multiple enlarged lymph nodes were shown in the left axillary and infraclavicular regions (Fig. (Fig.2).2 ). The patient did not receive further treatment and was discharged without any complications on March 26, 2016. Two days later, he reported to a superior hospital and underwent a positron emission tomography with integrated computed tomography (PET-CT) scan of the entire body. The scan showed several lesions with increased uptake in the left axillary and infraclavicular regions (Fig. (Fig.3),3 ), but no malignant lesions in other organs, especially in the mammary glands. The US examination on the same day also showed no lesions on the breast, and in addition, there was no manifestation of accessory breast or ectopic breast in the axilla. Mammography was strongly recommended but the patient declined.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g001.jpg
Open in a separate window
Figure 1

(A) Initial US revealed 3 hypoechoic swollen lymph nodes with clear boundaries; the largest mass was 4.3 cm × 2.3 cm in diameter. (B) Initial left breast US revealed hyperplasia of the mammary gland with a maximum scope of 18 mm × 18 mm.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g002.jpg
Open in a separate window
Figure 2

Chest CT showed an enlarged lymph node in the infraclavicular region (arrow) after the first surgery. CT = computed tomography.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g003.jpg
Open in a separate window
Figure 3

PET/CT scan of the entire body showed several lesions with increased uptake in the left axillary and infraclavicular regions (arrows) after the first surgery. PET/CT = positron emission tomography/computed tomography.

On April 4, 2016, the patient presented to our hospital. He had no history of disease other than an appendectomy 3 years ago, and no history of medication, particularly hormonal drugs. He had an 8 pack-years smoking history and was a nondrinker. His mother had died of gastric cancer and his father of heart attack. In a physical examination, a 6-cm surgical scar was found on the left axilla; around the scar, several palpable rigid nodules were found under the skin. No symptoms were found in either breasts or in other organs. Considering all the results above, pathologists and oncologists eventually concluded that this was a case of male OBC. We recommended a modified radical mastectomy, but he refused the mastectomy except for ALND. On April 7, 2016, he underwent his second surgery. Histological examination of paraffin sections with hematoxylin and eosin (HE) staining showed that only the left axillary (levels I and II) and infraclavicular (level III) lymph nodes were invaded by IDC, but no other lesions were found in the rest of the specimen. The tumor node metastasis (TNM) classification was T0N3aM0 Stage IIIC, according to 7th American Joint Committee on Cancer (AJCC) staging system of breast cancer. Histological examination showed that the structure of the lymph node was destroyed, and tumor cells with no clear boundaries were arranged in a prominent massive, diffusive, and nesting pattern. They were polygonal in shape, with abundant pink cytoplasm and large oval nuclei (Figs. (Figs.44 and and5).5 ). IHC staining (Figs. (Figs.668 ) showed positivity for CK7, GCDFP-15, EMA, and CEA, suspicious positivity for Her-2 (++), and negativity for ER, PR, GATA-binding protein-3 (GATA-3), CK20, and mammaglobin. The postoperative pathological report again revealed carcinoma in the left axillary and infraclavicular lymph nodes that metastasized from the breast. Because of the suspicious positivity for Her-2, the fluorescent in situ hybridization (FISH) method was strongly recommended but the patient declined because of inability to afford trastuzumab. After the surgery, the patient subsequently underwent adjuvant chemotherapy (AT scheme: adriamycin 40 mg day 1–2; docetaxel 130 mg day 1, every 3 weeks for 6 cycles). The treatment went smoothly, and the patient had good tolerance. Postoperative adjuvant radiation therapy on his remaining breast was delayed due to poor healing of the incision (wound infection). He told us that the wound healed in December 2016 and that he underwent radiation therapy in February 2017. The patient is currently being followed up without any signs of recurrence.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g004.jpg
Open in a separate window
Figure 4

Postoperative HE (original magnification ×100 for A and ×200 for B) staining. HE = hematoxylin and eosin.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g005.jpg
Open in a separate window
Figure 5

IHC staining (original magnification ×200) showing positivity for GCDFP-15. GCDFP-15 = gross cystic disease fluid protein-15, IHC = immunohistochemical.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g006.jpg
Open in a separate window
Figure 6

IHC staining (original magnification ×200) showing positivity for CK7. CK = cytokeratin, IHC = immunohistochemical.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g008.jpg
Open in a separate window
Figure 8

IHC staining (original magnification ×200) showing suspicious positivity for Her-2. Her-2 = human epidermal receptor-2, IHC = immunohistochemical.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g007.jpg
Open in a separate window
Figure 7

IHC staining (original magnification ×200) showing positivity for EMA. EMA = epithelial membrane antigen, IHC = immunohistochemical.

3. Discussion

In 1907, Halsted first described 2 patients with extensive carcinomatous involvement of the axilla by OBC.[ 1 ] Approximately 0.3% to 1.0% of breast cancer cases are OBC.[ 2 , 3 ] Breast cancer is rare in men, accounting for less than 1% of all malignances in men and only 1% of all cases of breast carcinoma.[ 4 , 5 ] The global incidence rates of male breast cancer vary widely by location and ethnicity.[ 6 ] MBC has a unimodal age distribution with a peak incidence at 71 years, differing from the bimodal distribution in female breast cancer (FBC).[ 7 ] Fentiman et al[ 4 ] reported that the majority of male breast cancers, including this case, are the invasive ductal type (85–95%), followed by ductal carcinoma in situ (10%), and therefore, the present case is among the majority. Male OBC is an extremely rare type of MBC or OBC. It was asymptomatic in the breast and usually discovered due to symptoms of metastasis in the axillary area, supraclavicular fossa, or infraclavicular fossa.[ 8 – 11 ] This is the sixth case report of male OBC in the literature. The characteristics of these cases are summarized in Table Table1.1 . Among these reported cases, the male OBC occurred from age 40 to 78, and thus, our case was the youngest.

Table 1

Summary of the cases reported on the male occult breast cancer.

An external file that holds a picture, illustration, etc.
Object name is medi-96-e9312-g009.jpg
Open in a separate window

Clinically, when only swollen axillary lymph nodes without a primary lesion are found, the first step is to clarify whether they are benign or malignant and then to confirm the original organ.[ 8 ] The most commonly reported palpable axillary masses are metastatic lymph nodes from breast cancer,[ 12 , 13 ] and followed by other malignancies including lung cancer, digestive tract cancer, hematological tumor, thyroid cancer, ovarian cancer, and accessory breast cancer. To avoid misdiagnosis, a comprehensive and systematic physical and imaging examination should be carried out to identify the primary origin. The absence of mammography or MRI of the breast is a drawback of our case report. It has been reported that magnetic resonance imaging (MRI) is a powerful tool to discover occult lesions that are not found by physical examination or routine imaging therapies such as CT and US.[ 14 – 16 ]

Our case is similar to the 5 reported cases diagnosed with male OBC. The cases had the following in common. First, the symptom was a painless palpable mass in the axilla. Second, both physical and imaging examinations revealed no primary lesions on the breast or other organs. Lastly, the tumor in the axillary lymph node was pathologically confirmed to have metastasized from the breast according to IHC. It has been concluded that the frequency of ER positivity in MBC is higher than that in female breast cancer (FBC), with more than 90% of tumors being positive for ER, and more than 80% positive for PR.[ 7 , 11 , 17 ] Therefore, the presence of both ER and PR plays a crucial role in determining whether the primary disease behind the axillary metastatic lymph node is breast cancer. In addition, even if both ER and PR are negative, breast cancer cannot be eliminated as a possible cause.[ 11 ] The case of male OBC reported by Gu et al,[ 9 ] as in our case, showed no expression of ER and PR. The final diagnosis was confirmed after consulting a number of pathologists and performing a series of examinations for differential diagnosis. The importance of carefully histological examination and IHC staining was particularly emphasized in the diagnosis of OBC. In diagnosing metastatic breast cancer, CK7 and CK20 are the most common IHC markers, and the differential diagnosis scope can be narrowed based on these markers. It has been reported that CK7 is usually positive and CK20 is usually negative in breast cancer. CK is expressed in more than 90% of breast cancer, whereas CK20 is mainly expressed in gastrointestinal tumors.[ 18 ] Another IHC marker of great importance is GCDFP-15,[ 19 ] which has a positive predictive value and a specificity of 90% in the diagnosis of breast cancer.[ 20 ] On the basis of all the results above, the patient was diagnosed with male OBC.

A standard surgical treatment for MBC is modified radical mastectomy.[ 11 ] By reviewing the 5 reported cases, we found that 4 in 5 patients underwent surgery. In the 4 patients, one of them underwent ALND only, whereas the others underwent both mastectomy and ALND. Walker et al[ 21 ] compared the 10-year overall survival (OS) of 596 OBC patients who underwent different treatments. The results showed that patients who underwent Mast (mastectomy plus ALND with or without postmastectomy radiation) or BCT (breast-conserving therapy with ALND and radiation) (n = 470) had a 10-year OS rate of 64.9% compared with 58.5% for patients who underwent ALND only (n = 126; P = .02) and 47.5% for patients who underwent observation only (n = 94; P = .04). The 10-year cause-specific survival (CSS) rate was 75.7% for patients who underwent BCT versus 73.9% for patients who underwent Mast (P = .55). Another study reported similar results.[ 22 ] We inferred that the postoperative radiation is crucial for OBC patients with axillary metastasis who undergo ALND only, similar to our case. To date, however, there have been no reports, on the therapeutic methods for male OBC.[ 11 ] Systematic treatment guidelines recommended for MBC default to postmenopausal FBC,[ 6 ] such as surgery combined with chemotherapy, radiotherapy, endocrine therapy, or targeted therapy. Therefore, we can infer that these guidelines are also used for male OBC. The patient in our case report had undergone chemotherapy and radiotherapy after surgery.

The axillary lymph node status has been accepted as one of the established factors that guides risk allocation in cases of OBC.[ 23 ] Studies have suggested that extensive lymph node involvement is an additional unfavorable prognostic factor for patients with OBC.[ 21 , 24 , 25 ] We suspected that our case might have a poor outcome because of the poor axillary lymph node status. Generally, breast cancer patients with poorly differentiated carcinoma had unfavorable prognoses, although the opposite is true for OBC patients. The majority of prognosis studies have shown that the OS of OBC is slightly better than that of breast cancer at a comparable nodal stage.[ 22 , 26 – 28 ] Male OBC may have its own characteristics that differ from female OBC or MBC, but little is known about male OBC due to its particularly low incidence rate. Multicentric and worldwide research of the biological features and classification of male OBC and further case registration are needed to acquire more data to guide clinical diagnosis and treatment.

Footnotes

Abbreviations: CEA = carcinoembryonic antigen, CK = cytokeratin, EMA = epithelial membrane antigen, ER = estrogen receptor, GCDFP-15 = gross cystic disease fluid protein-15, Her-2 = human epidermal receptor-2, IHC = immunohistochemical, OBC = occult breast cancer, PR = progesterone receptor, TTF-1 = thyroid transcription factor-1.

Funding: This study was supported by the National Key Research Program of China (No. 2016YFC0904700).

The authors have no conflicts of interest to disclose.

References

[1] Halsted WS.
I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg
1907;46:1–9. [ PMC free article ] [ PubMed ]
[2] Wang X, Zhao Y, Cao X.
Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J
2010;16:32–7. [ PubMed ]
[3] Baron PL, Moore MP, Kinne DW, et al.
Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg
1990;125:210–4. [ PubMed ]
[4] Fentiman IS, Fourquet A, Hortobagyi GN.
Male breast cancer. Lancet
2006;367:595–604. [ PubMed ]
[5] Jemal A, Murray T, Ward E, et al.
Cancer statistics, 2005. CA Cancer J Clin
2005;55:10–30. [ PubMed ]
[6] Hong JH, Ha KS, Jung YH, et al.
Clinical features of male breast cancer: experiences from seven institutions over 20 years. Cancer Res Treat
2016;48:1389–98. [ PMC free article ] [ PubMed ]
[7] Patten DK, Sharifi LK, Fazel M.
New approaches in the management of male breast cancer. Clin Breast Cancer
2013;13:309–14. [ PubMed ]
[8] He M, Liu H, Jiang Y.
A case report of male occult breast cancer first manifesting as axillary lymph node metastasis with part of metastatic mucinous carcinoma. Medicine (Baltimore)
2015;94:e1038. [ PMC free article ] [ PubMed ]
[9] Gu GL, Wang SL, Wei XM, et al.
Axillary metastasis as the first manifestation of occult breast cancer in a male patient. Breast Care (Basel)
2009;4:43–5. [ PMC free article ] [ PubMed ]
[10] Namba N, Hiraki A, Tabata M, et al.
Axillary metastasis as the first manifestation of occult breast cancer in a man: a case report. Anticancer Res
2002;22:3611–3. [ PubMed ]
[11] Hur SM, Cho DH, Lee SK, et al.
Occult breast cancers manifesting as axillary lymph node metastasis in men: a two-case report. J Breast Cancer
2012;15:359–63. [ PMC free article ] [ PubMed ]
[12] Park JE, Sohn YM, Kim EK.
Sonographic findings of axillary masses: what can be imaged in this space. J Ultrasound Med
2013;32:1261–70. [ PubMed ]
[13] Copeland EM, McBride CM.
Axillary metastases from unknown primary sites. Ann Surg
1973;178:25–7. [ PMC free article ] [ PubMed ]
[14] Schorn C, Fischer U, Luftner-Nagel S, et al.
MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol
1999;9:470–3. [ PubMed ]
[15] Morris EA, Schwartz LH, Dershaw DD, et al.
MR imaging of the breast in patients with occult primary breast carcinoma. Radiology
1997;205:437–40. [ PubMed ]
[16] Pentheroudakis G, Lazaridis G, Pavlidis N.
Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat
2010;119:1–1. [ PubMed ]
[17] Sousa B, Moser E, Cardoso F.
An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol
2013;717:71–83. [ PubMed ]
[18] Chu P, Wu E, Weiss LM.
Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol
2000;13:962–72. [ PubMed ]
[19] Kaufmann O, Deidesheimer T, Muehlenberg M, et al.
Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology
1996;29:233–40. [ PubMed ]
[20] Raju U, Ma CK, Shaw A.
Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study. Mod Pathol
1993;6:516–20. [ PubMed ]
[21] Walker GV, Smith GL, Perkins GH, et al.
Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer
2010;116:4000–6. [ PMC free article ] [ PubMed ]
[22] Sohn G, Son BH, Lee SJ, et al.
Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study. J Surg Oncol
2014;110:270–4. [ PubMed ]
[23] Goldhirsch A, Ingle JN, Gelber RD, et al.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol
2009;20:1319–29. [ PMC free article ] [ PubMed ]
[24] Merson M, Andreola S, Galimberti V, et al.
Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer
1992;70:504–8. [ PubMed ]
[25] Vlastos G, Jean ME, Mirza AN, et al.
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol
2001;8:425–31. [ PubMed ]
[26] Blanchard DK, Farley DR.
Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg
2004;28:535–9. [ PubMed ]
[27] Lacroix M, Toillon RA, Leclercq G.
Stable ’portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer
2004;11:497–522. [ PubMed ]
[28] Newman LA, Singletary SE.
Overview of adjuvant systemic therapy in early stage breast cancer. Surg Clin North Am
2007;87:499–509. xi. [ PubMed ]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

Formats:

  • Article
  • |

  • PubReader
  • |

  • ePub (beta)
  • |

  • PDF (809K)
  • |

  • Citation

Share

  • Share on Facebook
    Facebook
  • Share on Twitter
    Twitter
  • Share on Google Plus
    Google+

Support Center
Support Center

External link. Please review our privacy policy .
NLM
NIH
DHHS
USA.gov


National Center for
Biotechnology Information ,
U.S. National Library of Medicine

8600 Rockville Pike, Bethesda
MD, 20894
USA

Policies and Guidelines | Contact